



TCR² Therapeutics to Present at the 2017 UBS Global Healthcare Conference

Cambridge, MA, May 16, 2017 – TCR² Therapeutics Inc. announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a corporate overview at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 9:30 AM Eastern Time. The event will be held in New York at the Grand Hyatt New York.

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a \$44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

Media Contact:

Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com

###